INS and Insulin resistance: SULFs and glinides are insulin secretagogues [15], while TZDs are the only OADs specifically treating insulin resistance by activating the peroxisome proliferator-activated receptor γ (PPAR-γ), but their use in clinical practice is limited due to skepticism about safety and tolerability [16,17].